Evidence map›Paper›PMID 40308499›Full record

ArticleFrontiers in oncology2025

Application of DCE-MRI radiomics and heterogeneity analysis in predicting luminal and non-luminal subtypes of breast cancer.

Ming Yao, Dingli Ye, Yuchong Wang, Tongxu Shen, Jieqiong Yan, Da Zou, Shuangyan Sun

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Integrating deep learning and radiomics for precise identification of luminal A/B breast cancer subtypes on dynamic contrast-enhanced MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ming YaoDepartment of Radiology, Jilin Cancer Hospital, Changchun, China.
Dingli YeDepartment of Radiology, Jilin Cancer Hospital, Changchun, China.
Yuchong WangDepartment of Radiology, The First Hospital of Jilin University, Changchun, China.
Tongxu ShenDepartment of Radiology, Jilin Cancer Hospital, Changchun, China.
Jieqiong YanDepartment of Radiology, Jilin Cancer Hospital, Changchun, China.
Da ZouDepartment of Radiology, Pharmaceuticals Division, Bayer Healthcare Co. Ltd, Beijing, China.
Shuangyan SunDepartment of Radiology, Jilin Cancer Hospital, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The aim of this study was to explore the application value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) radiomics and heterogeneity analysis in the differentiation of molecular subtypes of luminal and non-luminal breast cancer. Methods: In this retrospective study, 388 female breast cancer patients (48.37 ± 9.41 years) with luminal (n = 190) and non-luminal (n = 198) molecular subtypes who received surgical treatment at Jilin Cancer Hospital were recruited from January 2019 to June 2023. All patients underwent breast MRI scan and DCE scan before surgery. The patients were then divided into a training set (n = 272) and a validation set (n = 116) in a 7:3 ratio. The three-dimensional texture feature parameters of the breast lesion areas were extracted. Four tumor heterogeneity parameters, including type I curve proportion, type II curve proportion, type III curve proportion and tumor heterogeneity values were calculated and normalized. Five machine learning (ML) models, including the logistic regression, naive Bayes algorithm (NB), k-nearest neighbor (KNN), decision tree algorithm (DT) and extreme gradient boosting (XGBoost) model were used to process the training data and were further validated. The best ML model was selected according to the performance in the validation set. Results: In luminal subtype breast lesions, type III curve proportion and heterogeneity index were significantly lower than the corresponding parameters of the non-luminal subtype lesions both in the training set and validation set. Eight features together with four heterogeneity-related parameters with significant differences between luminal and non-luminal groups were retained as radiomics signatures for constructing the prediction model. The logistic regression ML model achieved the best performance in the validation set with the highest area under the curve value (0.93), highest accuracy (86.94%), sensitivity (87.55%) and specificity (86.25%). Conclusion: The radiomics and heterogeneity analysis based on the DCE-MRI exhibit good application value in discriminating luminal and non-luminal subtype breast cancer. The logistic regression model demonstrates the best predictive performance among various machine learning models.

Indexed as

breast cancerheterogeneity analysismagnetic resonance imagingmolecular subtyperadiomics

Identifiers

PMID40308499
PMCPMC12040621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.